Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Vinblastine sulfate

HY-13780

(Vincaleukoblastine sulfate salt)

Vinblastine sulfate

Vinblastine sulfate Chemical Structure

Vinblastine sulfate can inhibit the formation of microtubule, it also inhibit nAChR(IC50=8.9 uM).

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $77 In-stock
5 mg $50 In-stock
10 mg $77 In-stock
50 mg $264 In-stock
100 mg $365 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €75 In-stock
5 mg €49 In-stock
10 mg €75 In-stock
50 mg €259 In-stock
100 mg €358 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Vinblastine sulfate
Cat. No.: HY-13780

Vinblastine sulfate Data Sheet

  • View current batch:

    Purity: 99.81%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

Customer View

Related Compound Libraries

Biological Activity of Vinblastine sulfate

Vinblastine sulfate can inhibit the formation of microtubule, it also inhibit nAChR(IC50=8.9 uM).
IC50 Value: VIN showed EC50 values of 15 ug/ml, against P815 mastocytoma cells in-vitro[1]. Also supresses nAChR activity with IC50 of 8.9 μM.
Target: Microtubule/nAChR
in vitro: At vinblastine concentrations of 0.5 uM and 2 uM, considerable inhibition of metabolic degradation of vinblastine was observed by competitive inhibitors of CYP3A4 (up to 60% inhibition), 2D6 (30%) and 2E1 (24%), while only a minor effect was observed for 2C9 (14%) and inhibitors of 1A2, 2C8 had no inhibitory effect on vinblastine metabolism. Vinblastine (0.5 and 2 uM) inhibited the metabolic capacity of CYP2C9 (up to 56%), 2C8 (36%), 2D6 (22%) and 3A4-mediated nifedipine oxidation (99%), while 3A4-mediated testosterone 6-beta-hydroxylation (max. 16%) as well as 1A2 and 2E1 remained unaffected[3].
in vivo: In combined intraperitoneal injection with vinblastine (200 micrograms kg-1) into P388/ADR-bearing mice, NA-382 in a suspension form (10 mg kg-1) prolonged the life-span of the mice near to that of P388/S-bearing mice treated with vinblastine alone, but verapamil even at the maximum tolerated dosage (30 mg kg-1) barely affected the in-vivo antitumour effect of vinblastine[2].
Clinical trial: Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma . Phase 3 Clinical
 

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 909.05 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C₄₆H₆₀N₄O₁₃S
CAS No 143-67-9
Solvent & Solubility

DMSO: ≥ 44 mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.1000 mL 5.5002 mL 11.0005 mL
5 mM 0.2200 mL 1.1000 mL 2.2001 mL
10 mM 0.1100 mL 0.5500 mL 1.1000 mL

Clinical Information of Vinblastine sulfate

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Vinblastine sulfate Cancer and Leukemia Group B Hodgkins disease 30-SEP-10 31-MAY-15 Phase 2 09-OCT-13
St Jude Children's Research Hospital Hodgkins disease 28-FEB-09 31-JUL-26 Phase 2 21-NOV-13
St Jude Children's Research Hospital Acute lymphoblastic leukemia 31-OCT-12 31-OCT-19 Phase 2 22-OCT-13
Eastern Cooperative Oncology Group Hodgkins disease 30-APR-12 01-JUN-21 Phase 2 14-SEP-13
Childrens Hospital of Philadelphia Neurofibromatosis type I 28-FEB-01 Phase 2 10-SEP-13

References on Vinblastine sulfate

Other Forms

Inhibitor Kit

Related Microtubule/Tubulin Products

  • 10-Deacetyl-7-xylosyl paclitaxel

    10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.

  • 10-Oxo Docetaxel

    10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.

  • 2-Methoxyestradiol

    2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.

  • 4'-Demethylepipodophyllotoxin

    4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.

  • 7-Epi-10-oxo-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).

  • 7-Epi-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.

  • 7-xylosyltaxol

    7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.

  • ABT-751

    ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.

  • Auristatin E

    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.

  • Auristatin F

    Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates.

MORE